One adult in ten will have diabetes by 2030

World Diabetes Day 2011 marks the release of the International Diabetes Federation's 5th edition of the Diabetes Atlas. New figures indicate that the number of people living with diabetes is expected to rise from 366 million in 2011 to 552 million by 2030, if no urgent action is taken. This equates to approximately three new cases every ten seconds or almost ten million per year. IDF also estimates that as many as 183 million people are unaware that they have diabetes.

In some of the poorest regions in the world such as Africa, where infectious diseases have traditionally been the focus of health care systems, diabetes cases are expected to increase by 90% by 2030. At least 78% of people in Africa are undiagnosed and do not know they are living with diabetes.

Other figures to be released today also show:

  • 80% of people with diabetes live in low and middle income countries.
  • 78,000 children develop type 1 diabetes every year
  • The greatest number of people with diabetes are between 40-59 years of age

"In every country and in every community worldwide, we are losing the battle against this cruel and deadly disease" said Jean Claude Mbanya, President of the International Diabetes Federation (IDF) "We want World Diabetes Day 2011 to bring these alarming diabetes facts into the global spotlight. We demand that public and world leaders act on diabetes now."

The release of these figures follow the September meeting of 193 Heads of State and government at the UN High Level Meeting in New York to agree on a Political Declaration on Non-Communicable Diseases (NCDs) including diabetes. This marks a major milestone for diabetes and other NCDs. However in some areas stronger commitments are needed.

"World leaders have recognised the magnitude and impact of these diseases and the urgent need for action. In some key areas we wanted stronger commitments and targets but the Declaration will accelerate international progress on diabetes and NCDs, saving millions of people from preventable death and disability" said Ann Keeling, CEO, International Diabetes Federation (IDF) and Chair of the NCD Alliance.

IDF is committed to translating UN Commitments into action by fostering a new level of partnership involving public, private and people.

It is hoped that campaigns such as today's World Diabetes Day will continue to raise the voice of people with diabetes and move from advocacy to action on a global scale.

For more information on the 5th edition Diabetes Atlas and country-by-country statistics visit: http://www.idf.org/diabetesatlas (online as of 14 November).

About World Diabetes Day
World Diabetes Day (WDD) is celebrated every year on November 14. The World Diabetes Day campaign is led by the International Diabetes Federation (IDF) and its member associations. It engages millions of people worldwide in diabetes advocacy and awareness. World Diabetes Day was created in 1991 by the International Diabetes Federation and the World Health Organization in response to growing concerns about the escalating health threat that diabetes now poses. World Diabetes Day became an official United Nations Day in 2007 with the passage of United Nation Resolution 61/225. The campaign draws attention to issues of paramount importance to the diabetes world and keeps diabetes firmly in the public spotlight.

About the International Diabetes Federation (IDF)
The International Diabetes Federation (IDF) is an umbrella organisation of over 200 national diabetes associations in over 160 countries. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. IDF's mission is to promote diabetes care, prevention and a cure worldwide.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...